Abstract Library

#4406 Fluorescence labelled plasma derived small extracellular vesicle as biomarkers in metastatic pancreatic neuroendocrine tumour patients

Introduction: Pancreatic neuroendocrine tumours (PanNET) are rare with increased annual incidence rate 1/lac. There are no specific biomarkers, diagnostic and prognostic tests available for PanNET. The small extracellular vesicles (sEV) play a key role in tumour growth and metastasis and can be a potential biomarker for metastasis of PanNET.

Conference:

Presenting Author:

Authors: As S, Gorai P, Naik M, Kumar R, Kumar S,

Keywords: Metastasis, Pancreatic neuroendocrine tumour, Small extracellular vesicles, Fluorescence, Nanoparticle tracking analysis,

#4168 BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

Introduction: A BRCA mutation denotes a genetic alteration found in either the BRCA1 or BRCA2 genes, both of which function as tumor suppressors. BRCA mutations are widely acknowledged for their link to breast and ovarian cancers, and rarely, to other malignancies such as the pancreas and prostate. Noteworthy, there have been limited reports associating BRCA mutations with NEN, and no possible co-relation to certain racial/ethnic populations has been reported to date.

Conference:

Presenting Author: Bel-Ange A

Authors: Bel-Ange A, Maimon O, Grozinsky-Glasberg S,

Keywords: BRCA gene mutation, NEN-neuroendocrine neoplasm,

#4150 Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis

Introduction: DCC functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Operating as a dependence receptor, DCC induces apoptosis without NTN and promotes cell survival in its presence. In some cancers like small cell lung cancer and neuroblastoma, upregulation of NTN-3 rather than NTN-1 has been observed. However, the precise involvement of NTNs and DCC in PNEN remains unclear.

Conference:

Presenting Author: Sela Peremen L

Authors: Sela Peremen L, Telerman A, Peshes Yaloz N, Tirosh A,

Keywords: neuroendocrine, netrin, pancreatic neuroendocrine tumor, dcc,

#3752 Loss of protein expression of tumor suppressor genes in neuroendocrine tumors – A tissue microarray analysis of 201 tumors from various organ sites

Introduction: Neuroendocrine tumors (NET) are a heterogenous group of tumors which differ in outcome based on their primary site. So far, data on inactivation of tumor suppressor genes in NET are mainly based on pancreatic and small intestine NET (pNET, siNET), whereas NET from other organ sites have not rigorously been analysed.

Conference:

Presenting Author:

Authors: Amin T, Viol F, Fründt T, Krause J, Fraune C,

Keywords: TMA, DAXX/ATRX, tumor suppressor, neuroendocrine tumor,

#3688 Novel von Hippel-Lindau-related pancreatic neuroendocrine neoplasms in-vivo model

Introduction: Von Hippel-Lindau (VHL) disease is a familial cancer syndrome caused by a germline mutation in the VHL tumor suppressor gene. Although VHL-related pancreatic neuroendocrine neoplasms (vPNEN) have been reported, their molecular pathogenesis is not fully investigated.

Conference:

Presenting Author:

Authors: Telerman A, Yossef Y, Chmelnik A, Tirosh A,

Keywords: VHL, PNEN, BON1, pseudohypoxia, CDX,